Keyphrases
Adverse Events of Special Interest
16%
Angioedema
16%
Angioedema Attack
100%
Attack Rate
66%
Domain Scores
16%
Hereditary Angioedema
100%
Initial Attack
16%
Injection Pain
16%
Injection Site Reaction
16%
Lanadelumab
100%
Long-term Efficacy
16%
Long-term Safety
16%
Quality of Life
16%
Rate 1
16%
Rate Reduction
16%
Sustained Efficacy
16%
Tolerability
16%
Treatment Duration
16%
Treatment-related
50%
Treatment-related Adverse Events
83%
Viral Respiratory Infections
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
83%
Angioneurotic Edema
100%
Injection Site Pain
16%
Injection Site Reaction
16%
Lanadelumab
100%
Tolerability
16%
Viral Upper Respiratory Tract Infection
16%